Ex 99.1 PASSAGE BIO REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS ● Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with longest follow-up ● Completed dosing of Cohort 1 (n=5) in upliFT-D trial; on track to deliver 6- month safety and biomarker data from Cohort 1 in 2H 2024 ● Plan to continue studying Dose 1 in Cohort 2 of upliFT-D t ...